Preservative-free bimatoprost 0.03% in patients with primary open-angle glaucoma or ocular hypertension in clinical practice

Código QR

Preservative-free bimatoprost 0.03% in patients with primary open-angle glaucoma or ocular hypertension in clinical practice

Lutz E Pillunat,1 Peter Eschstruth,2 Stefan Häsemeyer,3 Ulrich Thelen,4 Christian Foja,5 Richard Leaback,6 Stefan Pfennigsdorf7 1Department of Ophthalmology, University Hospital Carl Gustav Carus, Dresden, 2Ophthalmology Practice, Kiel, 3Eye Center Kraichgau, Wiesloch, 4Department of Ophth...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Pillunat LE, Eschstruth P, Häsemeyer S, Thelen U, Foja C, Leaback R, Pfennigsdorf S
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2016
Materias:	bimatoprost 0.03% intraocular pressure prostaglandin preservative-free benzalkonium chloride-free Ophthalmology RE1-994
Acceso en línea:	https://doaj.org/article/6da8ae26f416443db501a75c0ffe621b
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares

Preservative-free bimatoprost 0.03%/timolol 0.5% fixed combination in patients with glaucoma in clinical practice
por: Pfennigsdorf S, et al.
Publicado: (2016)

A combined analysis of four observational studies evaluating the intraocular pressure-lowering ability and tolerability of bimatoprost 0.01% in patients with primary open-angle glaucoma or ocular hypertension
por: Stevens A, et al.
Publicado: (2016)

Efficacy and tolerability of benzalkonium chloride-free travoprost in glaucoma patients switched from benzalkonium chloride-preserved latanoprost or bimatoprost
por: García-Feijoo J, et al.
Publicado: (2016)

The use of preservatives in dry eye drops
por: Walsh K, et al.
Publicado: (2019)

Evaluating intraocular pressure-lowering solutions for the treatment of open-angle glaucoma: comparison between bimatoprost 0.03% and bimatoprost 0.01% – an observational switch study
por: Deshpande SS, et al.
Publicado: (2017)

Real-life results of switching from preserved to preservative-free artificial tears containing hyaluronate in patients with dry eye disease
por: Nasser L, et al.
Publicado: (2018)

Effect of preservative removal from fixed-combination bimatoprost/timolol on intraocular pressure lowering: a potential timolol dose–response phenomenon
por: Shen J, et al.
Publicado: (2016)

Ocular pharmacokinetics and tolerability of bimatoprost ophthalmic solutions administered once or twice daily in rabbits, and clinical dosing implications
por: Shen J, et al.
Publicado: (2017)

Impact of Ocular Surface Disease Treatment in Patients with Glaucoma
por: Mylla Boso AL, et al.
Publicado: (2020)

Prospective, non-interventional, multicenter study of the intraocular pressure-lowering effects of prostaglandin analog/prostamide-containing therapies in previously treated patients with open-angle glaucoma or ocular hypertension
por: Tamçelik N, et al.
Publicado: (2017)

Safety and comfort evaluation of a new formulation of Visine® lubricant eye drops containing HydroBlend™ and GentlePur™
por: Torkildsen G, et al.
Publicado: (2016)

Preservative-free fixed combination of tafluprost 0.0015% and timolol 0.5% in patients with open-angle glaucoma and ocular hypertension: results of an open-label observational study
por: Pillunat LE, et al.
Publicado: (2017)

Patient considerations in ocular hypertension: role of bimatoprost ophthalmic solution
por: Lee D, et al.
Publicado: (2017)

Physical and mechanical properties of conventional glass ionomer cement incorporated with cationic substances
por: Dimkov Aleksandar G., et al.
Publicado: (2021)

Better tolerance of preservative-free latanoprost compared to preserved glaucoma eye drops: the 12-month real-life FREE study
por: Economou MA, et al.
Publicado: (2018)

Analysis of Bimatoprost-Induced changes on Rabbits eyelash Follicle: Clinical and Electron microscopic study
por: Sayed KM, et al.
Publicado: (2019)

Treatment with bimatoprost for exophthalmos in patients with inactive thyroid-associated ophthalmopathy
por: Higashiyama T, et al.
Publicado: (2018)

Impact of topical bimatoprost 0.01% and bimatoprost 0.03% on conjunctival irritation in rabbits
por: Abayomi B Ogundele, et al.
Publicado: (2010)

Physiochemical Properties and Cytotoxicity of a Benzalkonium Chloride-Free, Micellar Emulsion Ophthalmic Formulation of Latanoprost
por: Halder A, et al.
Publicado: (2020)

Exploring the Antimicrobial Action of Quaternary Amines against <italic toggle="yes">Acinetobacter baumannii</italic>
por: Gregory A. Knauf, et al.
Publicado: (2018)

Effect of systemic antihypertensives on change in intraocular pressure after initiating topical prostaglandins for primary open-angle glaucoma
por: Siddiqui M, et al.
Publicado: (2019)

Aqueous humor penetration of topical bimatoprost 0.01% and bimatoprost 0.03% in rabbits: response to authors
por: Chang-Lin J-E, et al.
Publicado: (2011)

Systematic Analysis of Efflux Pump-Mediated Antiseptic Resistance in <named-content content-type="genus-species">Staphylococcus aureus</named-content> Suggests a Need for Greater Antiseptic Stewardship
por: Patrick T. LaBreck, et al.
Publicado: (2020)

The renaissance of barrier contraception (based on the data from an international clinical trial)
por: Vera N. Prilepskaya, et al.
Publicado: (2021)

Detection of qacEΔ1, qacG, qacE, qacF resistance genes in Escherichia coli producing broad-spectrum beta-lactamases to benzalkonium chloride
por: F Hadadi, et al.
Publicado: (2019)

Real-World Study on Patient Satisfaction and Tolerability After Switching to Preservative-Free Latanoprost
por: Erb C, et al.
Publicado: (2021)

Ocular pharmacokinetics of bimatoprost formulated in DuraSite compared to bimatoprost 0.03% ophthalmic solution in pigmented rabbit eyes
por: Shafiee A, et al.
Publicado: (2013)

Effects of treatment with bimatoprost 0.03% for 3 years in patients with normal-tension glaucoma
por: Inoue K, et al.
Publicado: (2014)

Biological effects of an aqueous extract of Salix alba on the survival of Escherichia coli AB1157 cultures submitted to the action of stannous chloride
por: SOUZA,RAPHAEL S S, et al.
Publicado: (2009)

Intraocular pressure dynamics with prostaglandin analogs: a clinical application of water-drinking test
por: Özyol P, et al.
Publicado: (2016)

Managing refractory glaucoma with a fixed combination of bimatoprost (0.03%) and timolol (0.5%)
por: Moataz E Gheith, et al.
Publicado: (2008)

Fixed combination of travoprost and timolol maleate reduces intraocular pressure in Japanese patients with primary open-angle glaucoma or ocular hypertension: analysis by prostaglandin analogue
por: Nakano T, et al.
Publicado: (2016)

Dry sliding wear resistance characterization of titanium matrix composites reinforced with titanium carbonitrides
por: Hiroshi IZUI, et al.
Publicado: (2020)

Bimatoprost ophthalmic solution 0.03% lowered intraocular pressure of normal-tension glaucoma with minimal adverse events
por: Tsumura T, et al.
Publicado: (2012)

Bimatoprost ophthalmic solution 0.03% lowered intraocularpressure of normal-tension glaucoma with minimal adverse events [Corrigendum]
por: Tsumura T, et al.
Publicado: (2013)

Bimatoprost ophthalmic solution 0.03% lowered intraocular pressure of normal-tension glaucoma with minimal adverse events. [Corrigendum]
por: Tsumura T, et al.
Publicado: (2013)

Glaucoma therapy: preservative-free for all?
por: Thygesen J
Publicado: (2018)

Influence of EDTA and its Association with Benzalkonium Chloride on Enterococcus faecalis Adhesion to Dentin
por: Titato,Pedro Cesar Gomes, et al.
Publicado: (2020)

Switching to preservative-free latanoprost: impact on tolerability and patient satisfaction
por: Muñoz Negrete FJ, et al.
Publicado: (2017)

Bimatoprost 0.01% or 0.03% in patients with glaucoma or ocular hypertension previously treated with latanoprost: two randomized 12-week trials
por: Myers JS, et al.
Publicado: (2014)